文献速递儿童消化与营养儿童感染

儿童非血性腹泻预测炎症性肠病的检测策略

Test Strategies to Predict Inflammatory Bowel Disease Among Children With Nonbloody Diarrhea.
PubMed 文献 · Pediatrics · 2020-07-21

该前瞻性队列研究纳入193例6至18岁慢性非血性腹泻伴腹痛患儿,评估4种诊断策略预测炎症性肠病(IBD)的价值。症状联合血液和粪便标志物的AUC达0.997,为最优策略,可使100例中14例接受内镜,其中3例无IBD,且无IBD漏诊。

要点

  • 症状联合血液和粪便标志物预测IBD的AUC为0.997,优于其他策略。
  • 采用该联合策略分诊,100例中14例接受内镜,3例无IBD,无IBD漏诊。
  • 直肠出血或肛周疾病患者被排除,因这些表现直接提示内镜不论生物标志物。

核心结论

  • 评估症状联合血液和粪便标志物是非血性腹泻患儿预测IBD的最优检测策略,可帮助儿科医生将诊断性内镜保留给高风险患儿。

研究设计与样本

  • 前瞻性队列研究,纳入193例6至18岁在二级或三级医院接受标准化诊断检查的慢性非血性腹泻伴腹痛患者。
  • 排除有直肠出血或肛周疾病的患者,因这些表现直接促使内镜检查而不论生物标志物结果。

主要发现

  • 仅基于症状的基础预测模型AUC为0.718(95%CI:0.604-0.832)。
  • 加入血液或粪便标志物后AUC分别增至0.930(95%CI:0.884-0.977)和0.967(95%CI:0.945-0.990)。
  • 症状联合血液和粪便标志物的AUC为0.997(95%CI:0.993-1.000),优于所有其他策略。

关键数值与推荐

  • C反应蛋白>10 mg/L、血红蛋白<年龄和性别对应均值-2 SD、粪便钙卫蛋白≥250 μg/g作为标志物阈值。
  • 采用症状、血液标志物和钙卫蛋白联合分诊策略,100例中14例接受内镜,其中3例无IBD,无IBD患儿被漏诊。

临床怎么用

  • 对慢性非血性腹泻伴腹痛的患儿,可评估症状联合血液和粪便标志物以预测IBD风险。
  • 该策略有助于将诊断性内镜保留给高风险患儿,减少低风险患儿的内镜暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We evaluated 4 diagnostic strategies to predict the presence of inflammatory bowel disease (IBD) in children who present with chronic nonbloody diarrhea and abdominal pain. METHODS: We conducted a prospective cohort study including 193 patients aged 6 to 18 years who underwent a standardized diagnostic workup in secondary or tertiary care hospitals. Each patient was assessed for symptoms, C-reactive protein (>10 mg/L), hemoglobin (<-2 SD for age and sex), and fecal calprotectin (≥250 μg/g). Patients with rectal bleeding or perianal disease were excluded because the presence of these findings prompted endoscopy regardless of their biomarkers. Primary outcome was IBD confirmed by endoscopy or IBD ruled out by endoscopy or uneventful clinical follow-up for 6 months. RESULTS: Twenty-two of 193 (11%) children had IBD. The basic prediction model was based on symptoms only. Adding blood or stool markers increased the AUC from 0.718 (95% confidence interval [CI]: 0.604-0.832) to 0.930 (95% CI: 0.884-0.977) and 0.967 (95% CI: 0.945-0.990). Combining symptoms with blood and stool markers outperformed all other strategies (AUC 0.997 [95% CI: 0.993-1.000]). Triaging with a strategy that involves symptoms, blood markers, and calprotectin will result in 14 of 100 patients being exposed to endoscopy. Three of them will not have IBD, and no IBD-affected child will be missed. CONCLUSIONS: Evaluating symptoms plus blood and stool markers in patients with nonbloody diarrhea is the optimal test strategy that allows pediatricians to reserve a diagnostic endoscopy for children at high risk for IBD.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Van de Vijver E, Heida A, Ioannou S, et al. Test Strategies to Predict Inflammatory Bowel Disease Among Children With Nonbloody Diarrhea. Pediatrics. 2020. PMID: 32694147. doi:10.1542/peds.2019-2235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。